Přejít k hlavnímu obsahu

Research at the Laboratory of Integrative Genomics (LIG) centers on elucidating the molecular mechanisms governing DNA damage response and cellular stress pathways. These pathways are activated by a myriad of factors including, but not limited to, erroneous DNA replication, proteotoxicity, mechanical strain, and oxidative damage. Such pathways are pivotal for the sustenance of cancer cells and play a crucial role in conferring therapeutic resistance.

Our investigatory focus encompasses a wide range of cancer-specific hallmarks, such as heightened levels of DNA damage concomitant with mutational burden, challenges in DNA replication fidelity, accumulation of misfolded or dysfunctional proteins, free radical generation, nutrient scarcity, and hypoxic conditions. Through our specialized methods and domain expertise, we aim to directly interrogate and target these stress pathways within the cancer cellular milieu.

The implications of our research are manifold. They extend from the discovery of novel predictive markers to the optimization of existing anticancer regimens and the identification of innovative therapeutic targets. To achieve these aims, the laboratory is segmented into two primary research arms:

The "Cellular Stress" group, headed by Dr. Martin Mistrik, focuses on deciphering the complexities of cellular stress responses and their roles in cancer pathology.

The "DNA Replication Dynamics" group, under the direction of Dr. Pavel Moudry, specializes in exploring the intricacies of DNA replication processes, specifically in the context of malignancies.

  • DNA damage and repair and genomic instability
  • Proteotoxic stress and proteostasis
  • Mechanical stress
  • Oncogenic and free radicals stress
  • DNA replication and replication stress
  • PARP enzyme and its targeting
BUCHTOVÁ, T., Z. ŠKROTT, K. CHROMÁ, J. ŘEHULKA, P. DŽUBÁK, M. HAJDÚCH, D. LUKÁČ, S. ARAMPATZIS, J. BÁRTEK, M. MISTRÍK
Cannabidiol-induced activation of the metallothionein pathway impedes anticancer effects of disulfiram and its metabolite CuET. Molecular Oncology. 2021, 16(7), 1541-1554, ISSN: 1574-7891, PMID: 34632694,
MISTRÍK, M., Z. ŠKROTT, P. MULLER, A. PANACEK, L. HOCHVALDOVA, K. CHROMÁ, T. BUCHTOVÁ, V. VANDOVA, L. KVÍTEK, J. BÁRTEK
Microthermal-induced subcellular-targeted protein damage in cells on plasmonic nanosilver-modified surfaces evokes a two-phase HSP-p97/VCP response. Nature Communications. 2021, 12(1), 713, ISSN: 2041-1723, PMID: 33514738,
MAYA-MENDOZA, A., P. MOUDRÝ, J. MERCHUT-MAYA, M. LEE, R. STRAUSS, J. BÁRTEK
High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018, 559(7713), 279-284, ISSN: 0028-0836, PMID: 29950726,
CHROMÁ, K., Z. ŠKROTT, J. GURSKÝ, J. BACOVSKY, P. MOUDRÝ, T. BUCHTOVÁ, M. MISTRÍK, J. BÁRTEK
A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment. Cell Death & Disease. 2022, 13(3), 203, ISSN: 2041-4889, PMID: 35246527,
MOUDRÝ, P., K. CHROMÁ, S. BURSAC, S. VOLAREVIC, J. BÁRTEK
RNA-interference screen for p53 regulators unveils a role of WDR75 in ribosome biogenesis. Cell Death and Differentiation. 2022, 29(3), 687-696, ISSN: 1350-9047, PMID: 34611297,
Impaired ribosome biogenesis: mechanisms and relevance to cancer and aging. Aging-US. 2019, 11(8), 2512-2540, ISSN: 1945-4589, PMID: 31026227,
DISULFIRAM I (Škrott)
  1. Patent: EP 3459526. Granted: 24.2.2021. Ownership: Palacký University Olomouc. Inventors: Škrott Zdeněk, Mistrík Martin, Hajdúch Marián, Bártek Jiří, Džubák PetrZbořil Radek.
  2. Published Application PCT/EP2018/076098 under WO 2019/063601 (4.4.2019)
  3. Patent: US 11,766,404. Granted: 26.9.2023. Ownership: Palacký University Olomouc. Inventors: Škrott Zdeněk, Mistrík Martin, Hajdúch Marián, Bártek Jiří, Džubák PetrZbořil Radek.
  4. Patent: AU 2018340510. Granted: 5.8.2021. Ownership: Palacký University Olomouc. Inventors: Škrott ZdeněkMistrík MartinHajdúch MariánBártek JiříDžubák PetrZbořil Radek.
  5. EP 18774061.9 - patent pending.
  6. Patent: IL 273652. Granted: 2.1.2024. Ownership: Palacký University Olomouc. Inventors: Škrott ZdeněkMistrík MartinHajdúch Marián, Bártek Jiří, Džubák PetrZbořil Radek.
  7. Patent: CA 3,076,855. Granted: 26.4.2022. Ownership: Palacký University Olomouc. Inventors: Škrott ZdeněkMistrík MartinHajdúch Marián, Bártek Jiří, Džubák PetrZbořil Radek.
  8. Patent: KR 10-2456683. Granted: 14.10.2022. Ownership: Palacký University Olomouc. Inventors: Škrott ZdeněkMistrík MartinHajdúch Marián, Bártek Jiří, Džubák PetrZbořil Radek.
  9. Patent: JP 7149624. Granted: 29.9.2022. Ownership: Palacký University Olomouc. Inventors: Škrott ZdeněkMistrík MartinHajdúch Marián, Bártek Jiří, Džubák PetrZbořil Radek.
  10. Patent: MX 396,552. Granted: 17.10.2022. Ownership: Palacký University Olomouc. Inventors: Škrott ZdeněkMistrík MartinHajdúch Marián, Bártek Jiří, Džubák PetrZbořil Radek.

Status: Available

METHOD OF OBTAINING FOLLICULAR CELLS AND A DEVICE FOR CARRYING OUT THIS METHOD (Mistrík)
  1. Patent: CZ 304255. Granted: 18.12.2013. Ownership: Palacký University Olomouc. Inventors: MISTRÍK Martin, BÁRTEK Jiří
  2. Published Application PCT/CZ2013/000152 under WO 2014/086324 (12.6.2014)
  3. Patent: EP 2928382. Granted: 26.12.2018. Ownership: Palacký University Olomouc. Inventors: MISTRÍK Martin, BÁRTEK Jiří
  4. Patent: US 9,943,331. Granted: 17.4.2018. Ownership: Palacký University Olomouc. Inventors: MISTRÍK Martin, BÁRTEK Jiří
  5. EU Registered Trademark: EUTM 018714735. Registered: 8.11.2022. Ownership: Palacký University Olomouc

Status: Available

Projekt: Cellular stress in health and disease
Vedoucí: Mistrík Martin Ph.D., Moudrý Pavel Ph.D., Škrott Zdeněk Ph.D.
K dispozici: 3
Určeno pro: Doktorské studium
Senior research group
Junior research group